Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide and one of the infectious diseases severely affected by the emergence of antimicrobial drug resistance. The World Health Organization (WHO) estimates that 458 000 of the 10 million cases of TB that developed in the year 2017 were caused by Mycobacterium tuberculosis with resistance to rifampicin and isoniazid, defined as multidrug-resistant TB (MDR-TB) [1]. In 8.5% of all patients with MDR-TB it is estimated that M. tuberculosis is also resistant against at least one fluoroquinolone and one of the second-line injectable drugs (SLIDs) amikacin, capreomycin, and/or kanamycin fulfilling the current definition for extensively drug-resistant tuberculosis (XDR-TB) [1].
No takes yet. Share an insight, caveat, or question.
Lange et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: